Eli Lilly and Company (NYSE:LLY) Shares Up 2.8% Following Analyst Upgrade

Eli Lilly and Company (NYSE:LLY) traded up 2.8% during mid-day trading on Tuesday after JPMorgan Chase & Co. raised their price target on the stock from $1,300.00 to $1,400.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Eli Lilly and Company traded as high as $1,249.45 and last traded at $1,233.32. Approximately 2,855,569 shares were traded during trading, a decline of 11% from the average daily volume of 3,223,707 shares. The stock had previously closed at $1,200.06.

A number of other equities analysts also recently issued reports on the company. Cantor Fitzgerald increased their target price on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an “overweight” rating in a research note on Monday. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Friday, June 5th. Bank of America raised their target price on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Leerink Partners boosted their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Finally, Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, July 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,243.22.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan raised its price target on Eli Lilly to $1,400 from $1,300 and kept an overweight rating, signaling more upside after the stock’s strong run. Benzinga report on JPMorgan target hike
• Positive Sentiment: Shares are also benefiting from renewed confidence in Lilly’s obesity franchise, including the Medicare GLP-1 Bridge rollout and continued enthusiasm for its weight-loss and diabetes pipeline. Quiver Quantitative article
• Positive Sentiment: News that rival weight-loss developer Kailera Therapeutics posted disappointing test results helped underscore Lilly’s lead in the obesity market, sending a favorable signal for LLY’s competitive position. Yahoo Finance article
• Neutral Sentiment: Commentary from Jim Cramer argued the recent drug-stock pullback was a crowded-trade rotation and said the market may be underestimating Lilly’s long-term growth story, adding to bullish sentiment but not changing fundamentals directly. 247WallSt article
• Neutral Sentiment: Several articles highlighted Lilly as one of the market’s top healthcare names and a stock to watch, reflecting strong investor attention rather than a new company-specific catalyst. Motley Fool article
• Negative Sentiment: Some recent coverage still points to regulatory and pricing-policy risks, which remain a lingering overhang for Lilly and the broader drug sector even as the stock rallies. Insider Monkey article

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after buying an additional 1,006,885 shares in the last quarter. State Street Corp boosted its position in Eli Lilly and Company by 1.8% during the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after acquiring an additional 635,358 shares during the last quarter. Capital Research Global Investors grew its stake in Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after acquiring an additional 4,332,008 shares during the period. Morgan Stanley raised its holdings in Eli Lilly and Company by 2.7% in the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after acquiring an additional 407,166 shares during the last quarter. Finally, Capital World Investors raised its holdings in Eli Lilly and Company by 0.4% in the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after acquiring an additional 61,851 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 2.8%

The company has a market cap of $1.16 trillion, a PE ratio of 43.81, a price-to-earnings-growth ratio of 1.51 and a beta of 0.51. The business has a 50 day simple moving average of $1,065.45 and a two-hundred day simple moving average of $1,027.90. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same period in the prior year, the firm posted $3.34 earnings per share. The business’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 35.74 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.